人才培育
Opening Remarks: Fong-Chin Su 蘇芳慶, Ph.D. Yuh-Jzer Joung 莊裕澤, Ph.D. Hong-Jen Chang 張鴻仁, M.D., M.P.H.
Speakers: Lei Chuang 莊蕾潔, M.Sc., PMP Kent Cochran, MS Carl Firth, Ph.D. Jeng Her 何正宏, Ph.D. Jeff C. Hsu 徐基峰, Ph.D. Tim Hung 洪哲章, M.D./ Pharmacist M. Sherry Ku 顧曼芹, Ph.D. Ada H.C. Kung 龔曉嘉, Ph.D., MBA, DABT Frank Lee 李文豐, Ph.D. Su-Yueh Lin 林舒悅, R.Ph, M.S. Wade Lin 林宗緯 Karen Wen 溫國蘭, Ph.D. George Yeh 葉志鴻 Zhao Yi Yen
活動說明
二十一世紀邁入資源整合及資訊科技新紀元，製藥、生物科技、醫療器材公司、受委託機構、醫療照護提供者及學研界等跨領域專業人才相互合作，整合轉譯醫學、臨床開發、精準醫學、醫療器材及供應鏈管理等資訊，加速推動以患者為中心(patient-centric)的新藥及醫材發展。為了維持新藥、新醫材及複合型藥物等跨領域產品的發展，我們需要更多創新的融資及募資工具，以跨越組織間的障礙，降低投資風險，提高新藥及醫材上市的成功率。
近年台灣致力於建立國際生技醫藥品牌，政府亦投入大量資金，但進入後期開發階段的新藥或醫材仍較少。我們發現台灣需要培育更多新藥及醫材開發及策略規劃的專業人才。因此，2017年我們擴大本研討會的規模，不單繼續加強新藥及醫材的開發訣竅，更針對策略開發建立新的思維模式。在兩天的課程及工作坊中，藉由藥物開發、法規、商業模式這三個層面，共同審視新藥及醫材開發的技術面及商業面。本研討會將帶領大家整合各項專業，並藉由現場討論了解各領域實務操作方法，透過整合所有面向制定策略，以規畫完善新藥及醫材營運模式，成功推動新藥及醫材於國際上市，促進台灣生技醫療產業發展。
The 21st Century Life Sciences have entered an era of information and resource integration to allow all multidiscipline talents from different biopharmaceutical, biotech and medical device companies, contracted organizations, healthcare providers and academic researchers to collaborate together. With recent big data effort, we are able to integrate various data from new drug translational medicine, clinical development, precision medicine, medical devices and supply chain management to support a “patient-centric” new drug/device development effort. To sustain this level of cross-industrial alliance collaboration for new drug, new medical devices, and combinational drug development, we need more innovative financing and funding systems to cross organizational barriers, mitigate the investment risk and enhance probability of success in launching a new drug or device product onto the market.
In these few years, while we are dedicating our effort in building our own “Taiwanese Brand” in Biotech Industries, our government has invested millions and billions of funding into this effort; however, we have seen rather limited new molecules or devices to enter later development stages. We found that we still need more professionals in drug and medical device development as well as strategic planning. In 2017, we expand our symposium effort not only to continue building a solid “know-how” foundation in new drug/medical device development, but also to cultivate a new thinking paradigm in strategy development. In these 2-day lectures and workshops, we will examine both technical and business attributes following three interdependent developmental tracks in Drug Development, Regulatory and Business Development. And then, we will lead everybody to first develop strategies by integrating all attributes and to build “real-world” operations based on the established strategies.